Camurus Says Co And Lilly Enter Collaboration And License Agreement For Long-Acting Fluidcrystal® Incretins
Reuters
Jun 04, 2025
June 3 (Reuters) - Camurus AB:: *CAMURUS AND LILLY ENTER COLLABORATION AND LICENSE AGREEMENT FOR LONG-ACTING FLUIDCRYSTAL® INCRETINS *CAMURUS AB - ELIGIBLE FOR UP TO $870 MILLION IN MILESTONE PAYMENTS *CAMURUS AB - TO RECEIVE UP TO $290 MILLION IN UPFRONT AND MILESTONE PAYMENTS *CAMURUS AB - AGREEMENT INCLUDES UP TO FOUR LILLY PROPRIETARY DRUG COMPOUNDS
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.